



06-20-01

RECEIVED

1632

JUN 26 2001

TECH CENTER 1600/2900

Express Mail No.: EL 501 640 318 US

#5/a
py
1.3.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hong JIN *et al.*

Application No.: 09/724,416

Art Unit: 1632

Filed: November 28, 2000

Examiner: Not Yet Assigned

For: Recombinant RSV Virus Expression Systems and Vaccines
Atty Docket No.: 7682-052

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. § 1.111, please consider the following amendments and remarks prior to the examination of the above-captioned application.

AMENDMENTS

IN THE SPECIFICATION:

Marked up versions of the following amended paragraphs are attached as Exhibit A.

Please amend the Specification as follows:

On page 7, please replace the paragraph beginning, "FIG. 1. Schematic representation of the RSV/CAT construct (pRSVA2CAT)..." with the following paragraph:

-- FIG. 1. Schematic representation of the RSV/CAT construct

(pRSVA2CAT) used in rescue experiments. The approximate 100 nt long leader (SEQ ID NOs:1-5) and 200 nt long trailer regions (SEQ ID NOs: 6-14) of RSV were constructed by the controlled annealing of synthetic oligonucleotides containing partial overlapping complementarity. The overlapping leader oligonucleotides are indicated by the 1L - 5L shown in the construct. The overlapping trailer nucleotides are indicated by the 1T - 9T shown in the construct. The nucleotide sequences of the leader and trailer DNAs were ligated into purified CAT gene DNA at the indicate